A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Fulvestrant With or Without LY2835219, a CDK4/6 Inhibitor, for Women With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer
Phase of Trial: Phase III
Latest Information Update: 29 Sep 2019
Price : $35 *
At a glance
- Drugs Abemaciclib (Primary) ; Fulvestrant (Primary)
- Indications Advanced breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms MONARCH 2
- Sponsors Eli Lilly and Company; Eli Lilly Japan
- 29 Sep 2019 According to an Eli Lilly and Company media release, data from this trial were published in JAMA Oncology.
- 29 Sep 2019 According to an Eli Lilly and Company media release, data from this trial were presented at the European Society for Medical Oncology (ESMO) 2019 Congress in the Presidential Symposium.
- 29 Sep 2019 Results presented in the Eli Lilly and Company media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History